Non-muscle Invasive Bladder Cancer
📧 Sign up to get email alerts when something new happens for Non-muscle Invasive Bladder Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: BladMetrix Urine Test for Monitoring Recurrence in Non-Muscle Invasive Bladder Cancer
This entry notes a clinical trial (NCT07511517) evaluating the BladMetrix urine test to monitor recurrence in non-muscle invasive bladder ca…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC [Phase 2]
Phase 2 clinical trial evaluating the safety and efficacy of Cretostimogene Grenadanorepvec in high-risk non-muscle-invasive bladder cancer.…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer [Phase 2]
This clinical trial update reports a Phase 2 study of durvalumab plus monalizumab for non-muscle invasive bladder cancer, currently recruiti…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy [Phase 3]
A Phase 3 clinical trial is testing adding gemcitabine to the standard Bacillus Calmette-Guérin therapy for people with recurrent non-muscle…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Bladder EpiCheck Product Development Study
This clinical trial update indicates that Nucleix Ltd.'s Bladder EpiCheck product development study is currently recruiting to evaluate its …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) [Phase 2]
A Phase 2 study of Intismeran Autogene (V940) in combination with BCG for bladder cancer is currently recruiting, targeting non-muscle-invas…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Intravesical BCG vs GEMDOCE in NMIBC [Phase 3]
Phase 3 trial evaluating intravesical Bacillus Calmette-Guérin (BCG) versus GEMDOCE for non-muscle-invasive bladder cancer is currently acti…
-
CLINICAL_TRIALS withdrawal · 2026-04-02Clinical Trial Update: Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer [Phase 2]
Phase 2 trial of CG0070 for high-grade non-muscle invasive bladder cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer [Phase 1, Phase 2]
This update covers the completion of a Phase I/II study evaluating intravesical VG161, an oncolytic virus, for BCG-unresponsive non-muscle-i…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study of CG0070 After Transurethral Resection in Patients With IR NMIBC [Phase 1]
Clinical trial update for CG0070 in patients with non-muscle invasive bladder cancer following transurethral resection; Phase 1 study is cur…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
Clinical trial update noting ongoing recruitment for a study evaluating AI-enabled blue light enhanced cystoscopy for detecting bladder canc…
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer [Phase 1, Phase 2]
A phase 1/2 study evaluating intravesical Bacillus Calmette-Guérin in combination with ALT-803 (N-803) for non-muscle invasive bladder cance…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer [Phase 3]
A Phase 3 trial is evaluating intravesical Nadofaragene Firadenovec versus observation in participants with intermediate-risk non-muscle inv…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial [Phase 1, Phase 2]
The INVITE trial is investigating in-home intravesical chemotherapy for non-muscle invasive bladder cancer and is currently recruiting for P…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer [Phase 2]
This Phase 2 clinical trial assesses urinary tumor DNA-guided systemic immunotherapy for unresectable very-high-risk non-muscle-invasive bla…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer [Phase 2]
This document announces a Phase 2 trial evaluating dutasteride in patients with low-grade non-muscle-invasive bladder cancer and notes that …
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating intravesical ResQ133A, a recombinant Mycobacterium (rMBCG), for non-muscle invasive bladder cancer in …
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Effects of Microbiological and Immunological Factors on the Lower Urinary Tract
A University of Zurich clinical trial update exploring how microbiological and immunological factors influence the lower urinary tract acros…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
Clinical trial update notes expanded-access use of a recombinant Bacillus Calmette-Guérin (ResQ132EX) for Non-muscle invasive bladder cancer…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer [Phase 3]
This ClinicalTrials.gov entry updates the Phase 3 S1602 study evaluating different strains of Bacillus Calmette-Guérin (BCG) with or without…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) [Phase 3]
Phase 3 clinical trial evaluating Verity-BCG for safety and efficacy in BCG-naïve patients with intermediate- and high-risk non-muscle-invas…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer. [Phase 1]
This is a registry entry for a Phase I/II study evaluating JL19001 injection alone or in combination with BCG in patients with high-risk non…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer [Phase 3]
Phase 3 trial update assessing intravesical TARA-002 versus investigator's choice intravesical chemotherapy for BCG-naïve high-grade non-mus…
-
CLINICAL_TRIALS withdrawal · 2026-03-17Clinical Trial Update: A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy [Phase 3]
Relmada Therapeutics has withdrawn its Phase 3 trial of NDV-01 administered intravesically for BCG-unresponsive non-muscle invasive bladder …
-
CLINICAL_TRIALS withdrawal · 2026-03-17Clinical Trial Update: A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT [Phase 3]
A Phase 3 trial evaluating NDV-01 (sustained-release gemcitabine-docetaxel) for intermediate-risk non-muscle invasive bladder cancer followi…